Stockreport

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)

More Company Research Source: Business Wire

PDF Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment o [Read more]

EVENT DAY Stock performance from the time of news release until the following 4pm ET market close	LAST PRICE AT NEWS EVENT {{SecondSection.LastPriceAtNewsEvent}}	SINCE EVENT Multi-day stock performance from the time of the news release
{{FirstSection.LastPrice}}	LAST PRICE	{{SecondSection.LastPrice}}
{{FirstSection.VWapStr_AMP}} {{FirstSection.VwapEventTime}}	VWAP	{{SecondSection.VWapStr_AMP}} {{SecondSection.VwapEventTime}}
{{FirstSection.MaxUp}} High: {{FirstSection.EodHigh}}	MAX UP	{{SecondSection.MaxUp}} High: {{SecondSection.EodHigh}}
{{FirstSection.MaxDown}} Low: {{FirstSection.EodLow}}	MAX DOWN	{{SecondSection.MaxDown}} Low: {{SecondSection.EodLow}}
{{FirstSection.TodaysRangeStr_AMP}} {{FirstSection.RangEvg}}	POST NEWS RANGE	{{SecondSection.TodaysRangeStr_AMP}} {{SecondSection.RangEvg}}
{{FirstSection.PriceChange}} {{FirstSection.PriceChangeTriangle_AMP}}	PRICE CHANGE	{{SecondSection.PriceChange}} {{SecondSection.PriceChangeTriangle_AMP}}
{{FirstSection.PriceChangePercent}}	PRICE CHANGE PERCENTAGE	{{SecondSection.PriceChangePercent}}
{{FirstSection.Spx500}}	S&P 500 (SPX)	{{SecondSection.Spx500}}
{{FirstSection.VolumeImpactStr_AMP}}	VOLUME RATIO	{{SecondSection.VolumeImpactStr_AMP}}
{{FirstSection.Volume}}	VOLUME (SHARES)	{{SecondSection.Volume}}
{{FirstSection.TicksString}}	TICKS	{{SecondSection.TicksString}}
{{FirstSection.AvgTransactionSizeStr_AMP}}	AVG SHARES PER TRADE	{{SecondSection.AvgTransactionSizeStr_AMP}}

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

{{GreenBoxData.Blurb}}

Opt in for alerts from News Quantifed